Scientific Reports · 2020 · 32 citations · 43 references
Life SciencesImmunologyInfectious DiseasesInnate ImmunityMolecular ImmunologyMolecular VirologyAntigen RecognitionAntiviral ImmunityHuman Leukocyte Antigen SystemLymphocyte ActivationNatural Killer Cell BiologyNatural Killer Cell RegulationAdaptive Immune Responses To Viral InfectionEpstein-barr Virus LatencyImmune Effector Cell FunctionInhibitory Killer Cell Immunoglobulin-like ReceptorsKiller Cell Immunoglobulin-like Receptor-human Leukocyte Antigen InteractionsNatural Killer Cell Inhibitory SignalingReceptors
Natural killer (NK) cells control viral infection through the interaction between inhibitory receptors and human leukocyte antigen (HLA) ligands and bound peptide. NK cells expressing the inhibitory receptor NKG2A/CD94 recognize and respond to autologous B cells latently infected with Epstein-Barr virus (EBV). The mechanism is not yet understood, thus we investigated peptides derived from seven latent proteins of EBV in the interaction of NKG2A and its ligand HLA-E. Functional analysis demonstrated that EBV peptides can bind to HLA-E and block inhibition of NK cell effector function. Moreover, analysis of DNA from 79 subjects showed sequence variations in the latent protein, LMP1, which alters NK responses to EBV. We provide evidence that peptides derived from EBV latent cycle proteins can impair the recognition of NKG2A despite being presented by HLA-E, resulting in NK cell activation.
43
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Véronique M. Braud, David Allan, Christopher A. O'Callaghan et al. · Nature · 1998 · 2.2K citations
NetMHCpan, a method for MHC class I binding prediction beyond humans
Ilka Hoof, Bjoern Peters, John Sidney et al. · Immunogenetics · 2008 · 784 citations